{"id":"W2478515289","doi":"10.1200/jco.2016.34.18_suppl.lba4500","title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Atezolizumab; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Cohort; Cisplatin; Urology; Clinical endpoint; Radiation therapy; Cancer; Chemotherapy; Nivolumab; Clinical trial; Bladder cancer; Immunotherapy; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00113614,0.0004157745,0.0008184104,0.0003648767,0.0002668908,0.00096746,0.00065046,0.0005361742,0.002832686],"category_scores_gemma":[0.001073096,0.0002971418,0.001136042,0.000485565,0.0002766417,0.0005498656,0.0005450415,0.000896812,0.000626642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007424049,"about_ca_system_score_gemma":0.0006380174,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001424139,"about_ca_topic_score_gemma":0.003797126,"domain_scores_codex":[0.9995321,0.0001205244,0.00002754341,0.0001639588,0.00006479388,0.00009103306],"domain_scores_gemma":[0.9993252,0.00008793221,0.0002477494,0.0001012533,0.00004094476,0.0001969512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.08645657,0.002483152,0.8382157,0.0009099329,0.003490945,0.0006286572,0.0003448817,0.001725085,0.01125703,0.0002647071,0.01143954,0.04278393],"study_design_scores_gemma":[0.0116936,0.03277369,0.9340654,0.0002044424,0.002683745,0.0020654,0.0003034469,0.002599977,0.002290486,0.0002749696,0.01099502,0.00004973701],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885654,0.00139461,0.0001947338,0.0001121263,0.00001898655,0.0002170584,0.008537616,0.00003338357,0.0009260908],"genre_scores_gemma":[0.9844272,0.00044862,0.0002244362,0.0002615999,0.00003611716,0.0001564691,0.01361598,0.0000209846,0.0008086879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002832686,"threshold_uncertainty_score":0.009476244,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0732569150031822,"score_gpt":0.4317699527936819,"score_spread":0.3585130377904996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}